Please assess the completion status of the following clinical trial:

Trial Title: A Double-blind, Randomized, Controlled Trial of Quetiapine Versus Haloperidol for the Treatment of Delirium

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female age 18 -75 years~* Was admitted in Maharaj Nakhon Chiang Mai hospital~* Was diagnosed by the diagnostic criteria for DSM-IV-TR delirium due to a general medical condition or delirium due to multiple etiologies~* Delirious state (delirium) of the patients was confirmed by using name-assess confusion assessment method (CAM) and assessment of severity with delirium rating scale-revised-98 (DRS-R-98)~* Have a written consent from the legal representatives~Exclusion Criteria:~* Was diagnosed substance withdrawal delirium~* Having a history drug allergy either from quetiapine or haloperidol~* Female patients who are pregnant or breastfeeding~* No written consent from the legal representatives~* Received other anti-psychotic drug before attend the study~* Being ill with renal or hepatic failure

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- quetiapine (Type: EXPERIMENTAL): atypical antipsychotic drug
- haloperidol (Type: ACTIVE_COMPARATOR): typical antipsychotic drug

Based on this trial design, predict the completion outcome and termination type (if applicable).